Endoleaks Type II: no association with mortality

Original Title: Risk factors and consequences of persistent type II endoleaks. Reference: Ruby C. Lo et al. J Vasc Surg 2016;63:895-901

 

The presence of type II endoleaks is infrequent (1%-10%) and most cases resolve spontaneously at 12 months. When they don’t, there is still controversy as to whether they may be associated to aneurysm diameter increase or to aneurysm rupture requiring intervention or conversion to surgery.

2367 patients receiving endovascular aneurysm repair were analyzed; 1977 (84%) did not present leaks or presented transient endoleaks, and 390 patients presented persistent endoleaks at follow up.

There were no differences in anatomical characteristics of aneurysms between those with endoleaks and those without.

There were no difference in device type, but there was a higher rate of type II endoleaks with coil embolization to one or both hypogastric arteries (12% vs. 8% p=0.02) and also a higher rate of endoleaks when using extensions (12% vs. 8% (p=0.008).

Follow up was at mean 463 days and the presence of type II endoleaks was a predictor of reintervention (OR 15.3; CI 95% 9.7-24.3; p<0.01) but not of mortality (OR 1.1; CI 95% 0.9-1.6; p=0.477).

Conclusion
The presence of type II endoleaks in patients undergoing endovascular aneurysm repair to treat an abdominal aortic aneurysm is more frequent when there is coil embolization to one or both hypogastric arteries and when using extensions. Type II endoleak persistence is associated to an increase in reintervention but not to aneurysm rupture or mortality. This reinforces the need to control patients with type II endoleak persistence.

Editorial Comment
Though retrospective, and therefore weak, this is the largest study on type II endoleaks. Even so, it seems clear that type II endoleaks are not associated with hard events such as death or rupture.

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...